Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.

Fuliang ChuJingjing CaoJingwei LiuHaopeng YangTimothy J DavisShao-Qing KuangXiaoyun ChengZheng ZhangSwathi KarriLong T VienLaura BoverRyan Sun Francisco VegaMichael GreenRichard Eric DavisSattva S Neelapu

Published in: Journal for immunotherapy of cancer (2023)

Our results indicated that this novel CD79b CAR T-cell therapy product has robust antitumor activity against B-cell lymphomas. These results supported initiation of a phase 1 clinical trial to evaluate this product in patients with relapsed or refractory B-cell lymphomas.

Keyphrases

cell therapy
clinical trial
acute lymphoblastic leukemia
mesenchymal stem cells
acute myeloid leukemia
nk cells
multiple myeloma
hodgkin lymphoma
open label
randomized controlled trial